TMCnet News

Research and Markets: Insulin Glargine - 2015 Comprehensive Patent Search
[February 27, 2015]

Research and Markets: Insulin Glargine - 2015 Comprehensive Patent Search


Research and Markets (http://www.researchandmarkets.com/research/2v7krj/insulin_glargine) has announced the addition of the "Insulin Glargine - Comprehensive patent search" report to their offering.

Imagine having your own team of pharmaceutical patent experts at the click of a button.

Used by the world's leading pharmaceutical companies and legal teams for over 10 years, these searches are the benchmark in comprehensive, accurate and relevant patent data. Searched and analysed by highly trained, qualified staff using proprietary searching techniques, you won't need to worry about missing patents or updating data. And that means your IP staff will be freed up to concentrte on your business, rather than getting bogged down in patent data.



This report covers:

  • International Nonproprietary Name: Insulin Glargine
  • indications: Treatment of type 1 and type 2 diabetes mellitus for the control of hyperglycaemia
  • innovator:Sanofi-Aventis (Lantus, Lantus Optiset, Lantus Solostar, Optisulin, Optisulin Optiset, Optisulin Solostar)

Country coverage:


The In-depth search contains patents from territories that are individually verified and monitored for changes, including British, German, Spanish, French, US, Canadian, Australian, European, and PCT patents.

Access:

This report is provided through an online portal for a period of 12 months, for a maximum of 5 users. During this period, access to updates, excel exports, patent documents and national registers is provided at no additional charge.

Key Topics Covered:

Used by the world's leading pharmaceutical companies and legal teams for over 10 years, Ark In-depth Searches are the benchmark in comprehensive, accurate and relevant patent data. Searched and analysed by highly trained, qualified staff using proprietary searching techniques, you won't need to worry about missing patents or updating data. And that means your IP staff will be freed up to concentrate on your business, rather than getting bogged down in patent data.

For more information visit http://www.researchandmarkets.com/research/2v7krj/insulin_glargine


[ Back To TMCnet.com's Homepage ]